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Abstract
Background: Diabetes is a growing burden in sub-Saharan Africa where traditional medicines (TMs) remain a
primary form of healthcare in many settings. In Tanzania, TMs are frequently used to treat non-communicable
diseases, yet little is known about TM practices for non-communicable diseases like diabetes.
Methods: Between December 2013 and June 2014, we assessed TM practices, including types, frequencies, reasons,
and modes, among randomly selected community members. To further characterize TMs relevant for the local
treatment of diabetes, we also conducted focus groups and semi-structured interviews with key informants.
Results: We enrolled 481 adults of whom 45 (9.4 %) had diabetes. The prevalence of TM use among individuals
with diabetes was 77.1 % (95 % CI 58.5–89.0 %), and the prevalence of using TMs and biomedicines concurrently
was 37.6 % (95 % CI 20.5–58.4 %). Many were using TMs specifically to treat diabetes (40.3 %; 95 % CI 20.5–63.9),
and individuals with diabetes reported seeking healthcare from traditional healers, elders, family, friends, and herbal
vendors. We identified several plant-based TMs used toward diabetes care: Moringa oleifera, Cymbopogon citrullus,
Hagenia abyssinica, Aloe vera, Clausena anisata, Cajanus cajan, Artimisia afra, and Persea americana.
Conclusions: TMs were commonly used for diabetes care in northern Tanzania. Individuals with diabetes sought
healthcare advice from many sources, and several individuals used TMs and biomedicines together. The TMs
commonly used by individuals with diabetes in northern Tanzania have a wide range of effects, and understanding
them will more effectively shape biomedical practitices and public health policies that are patient-centered and
sensitive to TM preferences.
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Background
The prevalence of diabetes mellitus (DM) is rapidly
growing globally with a disproportionate burden falling
on low- and middle-income regions [1]. In sub-Saharan
Africa, DM prevalence is now as high as 18 % in some
countries and current estimates portend that the preva-
lence of DM in the region could nearly double by the
year 2045, which means that more than 40 million
people would be living with diabetes in sub-Saharan
Africa [2]. Despite this, access to biomedical health-
care remains limited for most populations in the
region [3, 4]. Health systems and healthcare clinics
are currently under-prepared to adequately meet the
demands of caring for non-communicable diseases
(NCDs) such as DM [5, 6]. In this setting, traditional
medicines (TMs), which are defined by the World
Health Organization (WHO) as “the sum total of the
knowledge, skills, and practices based on the theories,
beliefs, and experiences indigenous to different cul-
tures, whether explicable or not, used in the mainten-
ance of health as well as in the prevention, diagnosis,
improvement or treatment of physical and mental ill-
ness [7],” are critical in meeting the healthcare needs
for much of the population [8]. The WHO World
Health Assembly and regional committees, including
the WHO African regional committee and African
heads of states, have adopted resolutions which for-
mally recognized TMs as pivotal in health service
delivery. They also urged governments to integrate
TMs into their health system based on innovation
and research [7, 9–11]. However, in the context of
NCDs, for the most part these resolutions remain un-
met due to limited understanding of population-based
TM practices [12, 13].
In Tanzania, TM use is frequent with more than half
of all adults regularly using TM [14]. They are used for
treating a variety of conditions, including NCDs [12, 15].
However, little is known about the types, modes, fre-
quencies, reasons for use, and pharmacology of TMs
used to manage NCDs especially as they pertain to DM
[12–16]. Considering the burden of DM, characterizing
TM practices among community members with and at
risk for DM will be important in formulating optimal
disease management programs and public health efforts
in the region [13].
As part of the Comprehensive Kidney Disease Assess-
ment for Risk Factors, epidemiology, Knowledge, and
Attitudes (CKD AFRiKA) study in Northern Tanzania,
we conducted assessments among community-based
adults using focus-group discussions, in-depth inter-
views, and structured surveys. We sought to characterize
the use of TMs among a community-based population
in order to help shape public health efforts and biomed-
ical practices addressing DM in ways that are sensitive
to local TM practices. Specifically, we described TM prac-
tices among community members with DM including the
types, frequencies, modes, and pharmacological descrip-
tions of those relevant to DM care.
Methods
Study setting
The CKD AFRiKA Study was conducted in December
2013-June 2014 and March-June 2015 in the Kilimanjaro
Region of Tanzania. The region has an adult population
of 900,000 for which KCMC hospital serves as the ter-
tiary referral hospital. Patients pay a standard fee scaled
to their income for their clinical care at the hospital and
the hospital-based clinics [17]. The majority of the popu-
lation lives in rural settings (65 %). The unemployment
rate is 19 %, and the majority of adults have a primary
education or less (77 %). The largest ethnic group is the
Chagga tribe followed by the Pare, Sambaa, and Maasai
tribes. Swahili is the major language, and all participants
in our study spoke it as their first language [18].
Quantitative data collection
We developed a structured survey instrument designed
to test different factors related to TM practices among
community members (Additional file 1). The develop-
ment of the survey instrument has been previously
described [14, 19]. In brief, the instrument was drafted
in English by local and non-local experts from the fields
of medicine, epidemiology, sociology, anthropology, and
public health. It was independently translated into
Swahili by two native speakers with joint review of each
version. We piloted it through several qualitative ses-
sions in an iterative process in order to ensure the con-
tent validity of the survey instrument. The final version
of the survey instrument included nine items including
both open-ended questions related to types of TMs used
by community members as well as close-ended ques-
tions related to frequency of use, reasons for use, modes
of use, modes of access, and conditions treated by TMs.
Using two local surveyors, we verbally administered the
survey to adult community members from the Moshi
Urban and Moshi Rural districts of the Kilimanjaro
Region. The overall sample size was based on the require-
ments of the CKD AFRiKA study, which was designed to
estimate the community prevalence of chronic kidney
disease with a precision of 5 % when accounting for the
cluster-design effect. Using a random-number generator,
we selected thirty seven sampling areas from twenty-nine
neighborhoods, stratified by urban and rural. We based
the random neighborhood selection on probability pro-
portional to size using the 2012 Tanzanian National
Census [18]. Within each neighborhood the sampling area
was determined using geographic points randomly gener-
ated using Arc Global Information Systems (ArcGIS),
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v10.2.2 (Environmental Systems Research Institute,
Redlands, CA), and households were then randomly
chosen based on coin-flip and die-rolling techniques [20].
All adults living in the selected households were recruited,
and all Tanzanian citizens over the age of 18 were eligible
for inclusion. To reduce non-response rates, we attempted
a minimum of two additional visits on subsequent days
and weekends, and using mobile phone numbers, we
located eligible participants through multiple phone calls.
Qualitative data collection
As part of the CKD AFRiKA Study, we conducted focus
group discussions (FGDs) and in-depth interviews in a
central, easily accessible location. These sessions have
been described previously, but in brief, we conducted
five FGDs and 27 in-depth interviews both of which
included key informants from the community including
well-adults from the general population, chronically-ill
adults receiving care at the hospital medicine clinics,
adults receiving care from traditional healers, adults pur-
chasing TMs from herbal vendors, traditional healers,
herbal vendors, and medical doctors [14].
Disease definitions
Participants were assessed for DM as part of the CKD
AFRiKA Study [20]. Hemoglobin (Hb) A1c was mea-
sured from a fingerstick whole blood sample using the
Bayer A1c Now+ point-of-care device (Bayer Healthcare
LLC; Sunnyvale, CA). DM was considered present if the
HbA1c level was greater than 7.0 % (53 mmol/mol) or
current known use of anti-hyperglycemic medications
for the purpose of treating diabetes. We considered par-
ticipants to be at increased risk for diabetes if their
HbA1c was between 6.0 % (42 mmol/mol) and 6.9 %
(52 mmol/mol) in the absence of ongoing treatment
with anti-hyperglycemic medicines.
Data analysis and management
Quantitative data were analyzed using STATA v.13
(STATA Corp., College Station, TX). The median and
inter-quartile ranges (IQR) were reported for continuous
variables. All p values are two-sided at a 0.05 signifi-
cance level. To compare differences between groups, we
used a Chi squared test or Fisher’s Exact test. Prevalence
estimates were sample-balanced using age- and gender-
weights based on the 2012 urban and rural district-level
census data, and they are reported with 95 % confidence
intervals (CI) [21]. We used Taylor Series linearization
to account for the design effect due to cluster sampling.
All data were collected on paper and then electronically
entered into and managed using REDCap electronic data
capture tools hosted at Duke University. REDCap is a
secure, web-based application designed to support data
capture for research studies [21]. All data were verified
after electronic data entry by an independent reviewer to
ensure accuracy.
To identify traditional medicines used for the treatment
of DM, two authors (JL and DW) independently reviewed
the transcripts of the FGDs and in-depth interviews con-
ducted as part of the CKD AFRiKA Study. All TMs refer-
enced by participants were recorded in the coding index,
and analytic memos were created for TMs referenced for
treatment of DM. A third author (JO) familiar with local
languages, dialects, and customs, then cross-referenced
the local vernacular with known botanical and linguistic
catalogues in the region and country. Any discrepancies
were resolved by joint consensus. All of the qualitative
data, including the coding index, were recorded and
managed using NViVO v.10.0 (QRS International Pty Ltd,
Melbourne, Australia).
Results
Demographics of study participants
We enrolled 481 participants in the CKD AFRiKA
Study. Forty-five participants (9.4 %) had DM, and 84
(17.5 %) were at increased risk for DM. The household
non-response rate was 15.0 %, and the individual non-
response rate was 21.0 %. Compared to the regional cen-
sus data, men (p < 0.001) and young adults (18–39 years
old; p = 0.001) were more likely to be non-responders
[18]. The most common reason for non-response was
inability to locate or contact individuals.
Adults with DM were mostly female (n = 30;
66.7 %), ≥40 years of age (n = 40; 88.9 %), urban resi-
dents (n = 39; 86.7 %), ethnically Chagga (n = 26;
57.8 %), Protestant (n = 22; 48.9 %), and had a pri-
mary school education (n = 26; 57.8 %) (Table 1). The
median age of adults with DM was 59 (IQR 48–68)
years old. Several participants with DM were unaware
of having it (n = 16; 35.6 %), but many did report a
history of hypertension (n = 21; 46.7 %). Few reported
a history of heart disease, kidney disease, stroke,
chronic obstructive pulmonary disease (COPD), or
human immunodeficiency virus (HIV). Alcohol use
was common (n = 28; 62.2 %) but few reported a his-
tory of smoking (n = 13; 28.9 %).
Among those at increased risk for DM (n = 84),
most were female (n = 65; 77.4 %), ethnically Chagga
(n = 45; 54 %), urban residents (n = 63; 75.0 %), and
had a primary school education (n = 63; 75.0 %).
Unlike those with diabetes, they were younger (me-
dian age = 42 years; IQR 33–56)(p < 0.01) and were
more likely to be occupied as farmers or wage earners
(n = 32; 38.1 %)(p < 0.01).
Epidemiology of traditional medicine use
The prevalence of adults with DM reporting any TM
use was 77.1 % (95 % CI 58.5–89.0 %) (Table 2).
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Table 1 Participant characteristics by diabetes and diabetes risk status; CKD-AFRIKA study population, 2014; N = 481
Variable Participants






Male 123 (26 %) 89 (25 %) 19 (23 %) 15 (33 %)
Female 358 (74 %) 263 (75 %) 65 (77 %) 30 (67 %)
Age <0.01
18–39 years old 172 (36 %) 143 (41 %) 24 (29 %) 5 (11 %)
40–59 years old 191 (40 %) 135 (38 %) 37 (44 %) 19 (42 %)
60+ years old 118 (24 %) 74 (21 %) 23 (27 %) 21 (47 %)
Setting 0.10
Rural 111 (23 %) 84 (24 %) 21 (25 %) 6 (13 %)
Urban 370 (77 %) 268 (76 %) 63 (75 %) 39 (87 %)
Ethnicity 0.50
Chagga 288 (60 %) 217 (62 %) 45 (54 %) 26 (58 %)
Pare 66 (14 %) 43 (12 %) 19 (23 %) 4 (9 %)
Sambaa 27 (6 %) 22 (6 %) 3 (4 %) 2 (4 %)
Othera 100 (20 %) 70 (20 %) 17 (20 %) 13 (29 %)
Religion 0.18
Roman Catholic 192 (40 %) 149 (42 %) 31 (37 %) 12 (27 %)
Protestant 161 (33 %) 117 (33 %) 22 (26 %) 22 (49 %)
Islam 123 (26 %) 84 (24 %) 28 (33 %) 11 (24 %)
Hindu 2 (<1 %) 1 (<1 %) 1 (1 %) 0 (0 %)
Education 0.06
None 31 (6 %) 21 (6 %) 4 (5 %) 6 (13 %)
Primary 349 (73 %) 260 (74 %) 63 (75 %) 26 (58 %)
Secondary 74 (15 %) 52 (15 %) 12 (14 %) 10 (22 %)
Post-Secondary 27 (6 %) 19 (5 %) 5 (6 %) 3 (7 %)
Occupation <0.01
Unemployed 74 (15 %) 52 (15 %) 15 (18 %) 7 (16 %)
Farmer/Wage Earner 199 (41 %) 157 (45 %) 32 (38 %) 10 (22 %)
Small Business/Vendors 158 (33 %) 121 (34 %) 25 (30 %) 12 (27 %)
Professionalb 50 (10 %) 22 (6 %) 12 (14 %) 16 (36 %)
History of Smoking 117 (24 %) 85 (24 %) 19 (23 %) 13 (29 %) 0.45
History of alcohol intake 318 (66 %) 236 (67 %) 54 (64 %) 28 (62 %) 0.56
Self-Reported Medical History
Hypertension 134 (28 %) 86 (25 %) 27 (32 %) 21 (47 %) <0.01
Diabetes 61 (13 %) 23 (7 %) 9 (11 %) 29 (64 %) <0.01
Heart Diseasec 18 (4 %) 10 (3 %) 3 (4 %) 5 (11 %) 0.01
HIV 21 (4 %) 21 (6 %) 0 (0 %) 0 (0 %) 0.24
Stroke 8 (2 %) 6 (2 %) 0 (0 %) 2 (4 %) 0.17
COPD 8 (2 %) 6 (2 %) 1 (1 %) 1 (2 %) 0.55
Kidney Disease 14 (3 %) 7 (2 %) 3 (4 %) 4 (9 %) 0.03
COPD Chronic obstructive pulmonary disease
*P-value comparing differences by diabetes status (present or absent)
aOther ethnicities includes Maasai, Luguru, Kilindi, Kurya, Mziguwa, Mnyisanzu, Rangi, Jita, Nyambo, and Kaguru
bProfessional included any salaried position (e.g. nurse, teacher, government employee, etc.) and retired persons
cHeart disease included coronary disease, heart failure, or structural diseases
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Table 2 Epidemiology and characteristics of traditional medicine use stratified by diabetes and diabetes risk status; CKD-AFRIKA
Diabetes Absent; n = 436 (95 % CI) With Diabetes;
n = 45 (%, 95 % CI)Low risk (n = 352) Increased risk (n = 84)
Prevalence
…of TM Use 60.3 % (48.9–70.7) 56.7 % (43.4–69.2) 77.1 % (58.5–89.0)
…of concurrent TM and Biomedicine Use 4.9 % (2.7–8.9) 2.6 % (0.8–7.6) 37.6 % (20.5–58.4)
Incidence of TM Use (per year)
1–5 times 47.2 % (38.8–55.7) 32.0 % (19.9–47.1) 45.3 % (27.8–64.0)
6–10 times 7.7 % (4.6–12.6) 17.0 % (7.8–33.0) 5.2 % (1.5–16.1)
>10 times 5.4 % (3.1–9.4) 7.1 % (2.6–18.0) 26.7 % (10.2–53.8)
Reasons for TM Use
More Effective 83.3 % (74.6–89.4) 81.4 % (62.8–91.9) 79.6 % (40.4–95.7)
Lower Cost 60.1 % (48.2–70.9) 64.5 % (46.4–79.3) 55.2 % (32.2–76.2)
Easier to Access 69.9 % (61.0–77.6) 61.6 % (45.0–75.8) 59.1 % (30.7–82.5)
Safer 43.4 % (31.6–56.1) 39.1 % (25.8–54.2) 39.5 % (20.4–62.5)
More Traditional/Religious 30.4 % (23.4–38.4) 29.7 % (18.0–44.8) 42.0 % (24.1–62.3)
Modes of Healthcare Access
Medical Doctors 97.3 % (93.4–98.9) 97.2 % (85.3–99.5) 90.5 % (58.6–98.5)
Family and Elders 50.7 % (38.0–63.4) 55.4 % (34.4–74.6) 69.0 % (42.8–86.9)
Traditional Healers 5.6 % (2.7–11.0) 9.9 % (3.0–28.2) 22.9 % (8.2–49.7)
Pharmacists 19.9 % (11.9–31.3) 22.0 % (10.5–40.5) 10.6 % (3.9–25.5)
Herbal Vendors 3.9 % (1.1–12.2) 11.4 % (5.7–21.5) 5.1 % (1.5–16.1)
Friends/Neighbors 17.5 % (10.4–27.8) 16.7 % (9.7–27.4) 5.2 % (1.7–15.3)
TM Use
…for Symptomatic Ailments 57.3 % (49.2–65.0) 45.1 % (28.8–62.6) 79.1 % (60.8–90.2)
…for Chronic Diseases 27.7 % (19.1–38.0) 24.5 % (12.9–41.5) 57.0 % (29.4–80.9)
…for Reproductive/Fertility Ailments 22.8 % (14.6–33.9) 19.7 % (8.8–38.5) 49.5 % (28.2–70.9)
…for Malaria/Febrile Illnesses 56.7 % (43.1–69.4) 70.9 % (58.2–80.9) 59.2 % (28.7–84.0)
…for Spiritual/traditional uses 8.6 % (4.5–15.7) 7.0 % (2.2–20.2) 9.4 % (3.5–22.8)
…for Neurologic Illnesses 19.5 % (11.3–31.4) 19.6 % (10.2–34.5) 38.2 % (18.9–62.2)
…for Urogenital Conditions 15.7 % (9.8–24.4) 16.7 % (8.2–31.0) 26.0 % (10.6–51.1)
…for Cancers 14.7 % (6.6–29.7) 9.0 % (3.0–23.8) 22.9 % (8.0–50.6)
…for Disease Prevention 5.9 % (3.3–10.3) 0.7 % (0.1–5.8) 11.4 % (3.0–34.9)
…for Worms/Parasites 11.1 % (6.9–17.4) 15.9 % (9.3–25.9) 22.0 % (8.7–45.7)
Modes of TM Use
Mix with water 83.0 % (77.4–87.4) 85.7 % (75.2–92.3) 79.8 % (54.6–92.9)
Drink as a tea 61.1 % (52.7–68.9) 47.5 % (31.0–64.5) 62.7 % (35.0–83.9)
Drink as a soup 46.1 % (36.6–55.8) 35.2 % (25.5–46.4) 65.5 % (38.3–85.3)
Chew from the plant 57.5 % (46.4–67.9) 47.3 % (31.9–63.3) 58.3 % (41.6–73.3)
Drink with milk 22.8 % (15.7–31.9) 15.7 % (7.5–30.0) 39.2 % (19.2–63.6)
Bath 26.2 % (17.7–37.0) 30.3 % (20.7–42.0) 45.0 % (19.3–73.8)
Inhalation 33.9 % (26.5–42.1) 39.2 % (26.8–53.1) 42.5 % (24.0–63.3)
Powders 17.4 % (9.7–29.2) 22.9 % (11.8–39.7) 25.3 % (9.9–51.0)
As foods to be eaten 2.4 % (0.8–6.8) 7.7 % (2.0–25.5) 4.2 % (1.1–14.9)
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Most reported using TM 1–5 times per year (45.3 %;
95 % CI 27.8–64.0 %), but many also reported use of
more than 10 times per year (26.7 %; 95 % CI 10.2–
53.8 %). Fewer than half of adults with DM reported
ongoing use of any biomedicine (42.2 %; 95 % CI
24.3–62.4 %), and among these, nearly three-quarters
(n = 13; 72.2 %) were also using TMs. As such, among
all participants with DM, the prevalence of concur-
rent use of TM and biomedicine was 37.6 % (95 % CI
20.5–58.4 %), which did not vary significantly by age,
gender, occupation, or education (all p-values > 0.05).
Adults with DM reported many reasons for the use
of TMs (Table 2). When compared to biomedicines,
the prevalence of TMs being reported as more effect-
ive was 79.6 % (95 % CI 40.4-95.7 %), as easier to
access 59.1 % (95 % CI 30.7–82.5 %), as having lower
costs 55.2 % (95 % CI 32.2–76.2 %), as being more
traditional/religious 42.0 % (95 % CI 24.1–62.3 %),
and as being safer was 39.5 % (95 % CI 20.4–62.5 %).
Community members with DM accessed healthcare
from several sources (Table 2). Although most of
them reported accessing healthcare from medical doc-
tors (90.5 %; 95 % CI 58.6–98.5 %), many also
reported accessing healthcare from family and elders,
traditional healers, and pharmacists. Some also re-
ported seeking healthcare from herbal vendors (5.1 %;
95 % CI 1.5–16.1 %) and friends/neighbors (5.2 %;
95 % CI 1.7–15.3 %). Individuals with DM reported
using TMs most commonly for symptomatic ailments,
malaria/febrile illness, chronic diseases, neurologic
conditions, and reproductive/fertility ailments. The
most common modes reported were mixing with
water, tea, soup, or milk. Less frequently, they were
reported as being inhaled, chewed, used with baths,
lotions/creams, powders, or pill forms.
Many individuals were using TMs specifically for
the treatment of their DM. The prevalence of TMs as
a treatment choice for DM specifically was 40.3 %
(95 % CI 20.5–63.9). The prevalence of TMs alone as
the treatment choice for DM was 29.1 % (95 % CI
13.4–52.0) which was comparable to the prevalence
of biomedicine alone (27.8 %; 95 % CI 13.0–49.8) as
the treatment choice for DM (Fig. 1). Most
commonly, individuals with DM were receiving no
treatment (31.9 %; 95 % CI 14.4–56.5 %), either in
the form of TM or biomedicine.
The prevalence of TM use was also high (56.7 %;
95 % CI 43.4–69.2 %) among adults at increased risk
for DM (Table 2). Most reported using TMs 1–5
times per year (32.0 %; 95 % CI 19.8–47.2 %) or 6–10
times per year (17.0 %; 95 % CI 7.8–33.0 %). How-
ever, unlike adults with DM, those at risk for DM
had a lower prevalence of biomedicine use (4.3 %;
95 % CI 1.7–10.4 %).
Traditional medicines used for the treatment of diabetes
in Northern Tanzania
We identified 168 plant-based TMs referenced by partici-
pants as part of the qualitative sessions and open-ended
structured survey items. Three of these TMs were directly
referenced as being used for the treatment of DM: Mor-
inga (Moringa oleifera), lemongrass (Cymbopogon citrul-
lus), and African redwood (Hagenia abyssinica) (Table 3 &
Additional File 2). We further identified five plant-based
TMs relevant in the treatment and management of DM.
These were referenced as being in use by the local popula-
tion for other conditions (Table 4 & Additional File 2):
Aloe (Aloe vera), Horsewood (Clausena anisata), Pigeon
pea (Cajanus cajan), African wormwood (Artimisia afra),
and Avocado (Persea americana). All of the TMs were
identified as relevant for DM care had a wide-range of ef-
fects that could be potentially beneficial or harmful.
Discussion
The prevalence of TM use was high among individuals
with DM and those at increased risk for DM in Northern
Tanzania, and the plant-based TMs commonly used to-
wards DM care had numerous effects. Individuals with
and at risk for DM sought healthcare advice from many
non-biomedical practitioners including family members,
community and tribal elders, friends, traditional healers,
and herbal vendors. In addition, TMs were a common
treatment choice for DM, and many individuals with DM
used TM and biomedicine concurrently.
TMs are now recognized globally as important compo-
nents of healthcare systems [9–11, 13]. In sub-Saharan
Table 2 Epidemiology and characteristics of traditional medicine use stratified by diabetes and diabetes risk status; CKD-AFRIKA
(Continued)
Pill/Vitamin form 0.6 % (0.2–1.7) 1.4 % (0.3–6.7) 2.4 % (0.4–13.0)
Lotions/Creams 5.3 % (2.9–9.5) 5.8 % (2.1–15.1) 21.0 % (5.9–53.2)
Chronic Diseases: Hypertension, Heart problems, Diabetes, or Body Swelling
Reproductive/Fertility Ailments: Sexual Arousal/Virility, Menstrual Problems, Pregnancy Termination, or Fertility/Impotence
Neurologic illnesses: Epilepsy, Mental Confusion, or Depression
Spiritual/Traditional: Peace of mind/Ward off curses, Protection from ‘evil eyes’, Unexplained Illnesses, or ‘To Improve Luck’
Symptomatic Ailments: Increase Strength, Constipation, Increase energy, Digestion/Stomach problems, Fatigue, Arthritis/joint pains, Flu/Cold symptoms,
Headaches, or Skin problems
Urogenital: Kidney problems or Urinary problems
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Africa, TMs remain critical in meeting the healthcare
needs for many individuals. However, with the rising
burden of NCDs across sub-Saharan Africa [3, 4], the
continued role and importance of TMs in NCD manage-
ment is less clear. As such, our study, which highlights
TM practices among individuals with diabetes in north-
ern Tanzania, fills an important gap. In resource-limited
health facilities across Tanzania and sub-Saharan Africa,
taking a patient- or community-centered approach that
is sensitive to treatment preferences may be most ef-
fective, especially for improving NCD management. For
example, understanding high and low risk plant-based
TMs may be one approach to incorporate TM prefer-
ences into an NCD management program [22–24].
Additionally, educating TM practitioners and other key
stakeholders about safe and appropriate NCD care,
including timely referrals to biomedical practitioners,
may also be an effective approach to incorporate TM
preferences into NCD management programs. Other
potential strategies could include training community
health workers to deliver locally-relevant medical care
to patients with DM, developing community-based out-
reach programs that include DM education consistent
with local health belief systems and practices, or in-
corporating family members and caregivers into health
interventions [4, 14].
In order to develop such programs and policies, we need
to facilitate healthcare decisions that can leverage the ben-
efits of TMs while mitigating the risks. As such, a better
understanding of the clinical safety, efficacy, and quality of
TMs in local settings is urgently needed. Moreover, gov-
ernments should establish a framework for accreditation,
registration, and regulation of TM practitioners [22, 23].
Among the TMs that we identified, they all had numerous
pharmacologically active compounds and a variety of ef-
fects. Potential beneficial effects for individuals with DM
included blood pressure lowering, anti-microbial, anti-
inflammatory, anti-oxidative, and lipid lowering proper-
ties. Additionaly, several of them, including Cymbopogon
cirtullus [25, 26], Moringa oleifera [27], Aloe vera [28],
Clausean anista [29], Cajanus cajan [30, 31], Persea
americana [32] and Artimisia afra [33], also had direct
glucose-lowering effects, with some having specific effects
on glucose metabolism.
On the other hand, all the TMs we identified also had
potentially harmful side effects, including nephrotoxicy,
optic atrophy, hepatotoxicity, and volume depletion
among others, which may be particularly relevant for
individuals with DM who often suffer several co-
morbidities. Our findings extend the work of others
across the region by stressing the importance of equip-
ping both biomedical providers and traditional healers
with resources and education that can facilitate
evidence-based discussions regarding TM use among
their patient populations. For example, Clausena anisata
(Horsewood) has numerous potential benefits for indi-
viduals with DM, including blood pressure lowering
through inhibition of angiotensin-converting enzyme,
which may be particularly important among those with
proteinuria [34]. However, it also exhibits a dose-
dependent inhibition of many reverse transcriptase
inhibitors commonly used in the treatment of HIV [35].
Also, Aloe vera is commonly and effectively used topic-
ally to treat burns and minor skin conditions, but when
boiled and ingested in large amounts to treat dyspepsia,
it can cause acute kidney and liver injuries. Therefore,
through understanding these important effects and prac-
tices, providers caring for individuals with DM may be
able to tailor interventions in ways that are effective yet
also patient-centered and sensitive to healthcare-seeking
preferences.
We noted a few limitations in our study. Our cross-
sectional design does not allow causal pathways to be
established and associations may be confounded by
unmeasured variables. Additionally, non-response bias
may be present, and to reduce this potential bias we used
sample-balanced weights when reporting prevalence esti-
mates. Also, around culturally sensitive topics such as
Fig. 1 Treatment choices for diabetes care among individuals with diabetes in Northern Tanzania; CKD AFRiKA, 2014. *Prevalence rates were
sample-balanced using age- and gender-weights based on the 2012 district-level census data
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Table 3 Plant-based traditional medicines used for treatment of diabetes in the Kilimanjaro Region, Tanzania










Mlonge Senegal: stimulates breastmilk production,
diabetes, anxiety, diarrhea and dysentery,
colitis, gonorrhea, and various skin infections
Chad: nutritional supplementation
Nigeria and Benin: toothaches, GI ailments
(dyspepsia, ulcers, and aiding digestion), poor
vision, joint pains, diabetes, anemia, hypertension,
paralysis, and helminthic infestation
Uganda: diabetes, hypertension, HIV/AIDS-related
symptoms, stimulates breastmilk production
Leaf extracts have glucose metabolism
effects: modulates gene-expression of
gluconeogenic liver enzymes, and
regenerates pancreatic beta cells
Nitrile and mustard oil glycosides:
lowers blood pressure
Seed kernels: bronchodilatory properties




Anti-oxidative properties: may prevent
drug-induced nephrotoxicity, myocardial
damage, and gastric mucosal irritation
Active compounds: salicylic and ferulic acids,
flavonoids, phenolic acids, glucosinolates




















Lemongrass Mchaichai Southern Africa: diabetes, oral thrush,
anti-tussive, anti-emetic, antiseptic, arthritis
West Africa (Cameroon & Nigeria):
antipyretic/anti-malarial, stimulant,
anti-spasmodic, jaundice
Mauritius: common cold, pneumonia, fever,
GI ailments and dyspepsia
Oil extracts: anti-bacterial, anti-amebic, anti-fungal,
antimalarial, anti-protozoal, and antifilarial effects
Phenol and flavonoids: antioxidative
Citral: insect repellent
Active compounds: terpenes, alcohols, ketons,





















Ethiopia: Helminthic infections, Typhoid fever,
wound healing, epilepsy, sexually transmitted
diseases, and symptomatic ailments (dyspepsia,
diarrhea, common cold, and cough)
Essential oils: trypanocidal (anti-spasmodic) and
cytotoxic (in vitro activity against leukemic and
adenocarcinoma cell lines)
Active compounds: kosin (a phloroglucinol),
& quercetin glucuronides







CNS central nervous system, CYP3A4 Cytochrome P450 3A4, GI gastrointestinal


















Table 4 Plant-based traditional medicines relevant for the treatment and management of diabetes in Kilimanjaro Region, Tanzania
Nomenclature Uses in other African communities Active Compounds and Pharmacology Plant
Parts used












Aloe, Alovera Southern Africa: arthritis, burns/skin
conditions, hypertension, purging/laxative,
dyspepsia, anti-inflammatory, cosmetics, eye
ailments/conjunctivitis, sexually transmitted
diseases, infertility, impotence
East Africa (Kenya, Uganda, Ethiopia, and
Tanzania): malaria, purging/laxative for
cleansing purposes, dyspepsia, skin
ulcerations/wound healing including
burns, HIV/AIDS, cosmetic, infertility,
anti-parasitic
Gel: Prostaglandin- and bradykinase-mediated
anti-inflammatory activity.
Aloin leaf extracts: increases GI motility
and induces emesis
Active compounds: glucomannans,
thiamine, niacin, riboflavin, bradykinase,
















Horsewood Mjafari West Africa: bacterial and fungal infections
of the skin including boils, ringworm, and
eczema
East Africa (Tanzania): oral candidiasis,
fungal infections of the skin, and epilepsy
Southern Africa: epilepsy, arthritis, rheumatism
and other inflammatory conditions, hypertension,
heart failure and other heart ailments, schistosomiasis,
taeniasis and other parasitic infections, constipation
and dyspepsia; malaria and other febrile conditions,
headaches, eye ailments/conjunctivitis, impotence
and infertility
Leaf extracts inhibit ACE: may lower blood
pressure
Bacteriostatic against gram positive and
gram negative bacteria; Fungicidal activity
against Aspergilus fumigatus
Antiplasmodial: in-vitro dose-dependent
schizonticidal effect of leaf extracts on
parasitemia
In vitro activity against leukemic cell lines
Anti-HIV1/2 effects: dose-dependent inhibition
of reverse transcriptase and taq polymerase enzymes
Hypoglycemic properties (reduction in basal blood
glucose levels); Anti-convulsant; ACE inhibition;
Cyclooxygenase-1 and -2 (weak) inhibition
Active compounds:
Clausamine, carbazole alkaloids (girinimbine,












Pigeon pea Majani ya
mbaazi
Ghana: diabetes, dysentery, hepatitis, measles,
dysmenorrhea
Nigeria: wound healing, aphthae, bedsores,
and malaria/fever
Antibacterial activity; hypocholesterolemic effects
(diet-induced); inhibits CNS voltage-gated Na channels;
induces apoptosis in human breast cancer cells via a
ROS-mediated mitochondrial pathway; inhibits TNF-α
and IL-1β production
Glycemic profile: leaves induce hyperglycemia,
seeds induce hypoglycemia
Active compounds:



















East Africa (Kenya, Uganda, Tanzania, Zimbabwe,
Mozambique): dengue vector control, diarrhea,
Anti-inflammatory, limiting lowering (β-Carotene
and fatty acids), anticonvulsive (via gabanergic
effects) & vasodilatory properties; Inhibits
alpha-amylase and enhance glycogenesis;
acetogenins inhibit platelet







-Increased risk of bleeding when























Table 4 Plant-based traditional medicines relevant for the treatment and management of diabetes in Kilimanjaro Region, Tanzania (Continued)
sore throat, menstrual regulation, hair growth,
epilepsy, toothaches, wound healing, tuberculosis,
neuralgia)









Southern Africa: coughs, colds, sore throat,
gastritis/reflux, hemorrhoids, fevers, malaria,
asthma, diabetes
Lowers blood glucose, improves glucose
tolerance and balance in lipid metabolism;
anti-oxidative properties











GI gastro-intestinal, ACE angiotensin converting enzyme, TNF tumor necrosis factor, IL interleukin, CNS central nervous system, ROS reactive oxygen species


















TMs, reporting and recall bias are a concern. To reduce
these biases, we used only local native surveyors who
spoke Swahili as their first language, conducted the inter-
views in private when possible, and pre-tested the survey
instruments for content validity and design flaws. Mis-
classification of disease may also be present, and though
we expect most misclassification to be non-differential,
the measurement we used to diagnose diabetes (HbA1c)
has not been validated in this population. As such, the
sensitivity and specificity of the test at a cutoff value of
7.0 % (53 mmol/mol) are not known for this population.
Conclusion
In conclusion, the prevalence of TM use was high among
individuals with DM as well as those at increased risk for
DM in northern Tanzania, and many of these individuals
use TMs and biomedicines together. Individuals with DM
sought healthcare advice from several sources, and bio-
medical providers need to be aware of these practices,
especially as they pertain to TM use. The TMs commonly
used by individuals with DM in northern Tanzania have a
wide range of effects, and understanding these effects will
help shape biomedical practitices and public health pol-
icies that are effective yet also patient-centered and sensi-
tive to local TM preferences.
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